Home>Topics>Companies>Gilead Sciences

Gilead Sciences GILD

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Gilead shares dip after warning about hepatitis C drug interaction


      Mon, 23 Mar 2015

      March 23 (Reuters) - Gilead Sciences Inc shares slid 2 percent on Monday after the company warned about potentially fatal risks for patients being treated with its top-selling hepatitis c drugs who also take the potent heart drug amiodarone.

    2. Charity attacks Gilead over hepatitis C drug restrictions


      Wed, 18 Mar 2015

      March 18 (Reuters) - Charity Medecins Sans Frontieres has accused U.S. drugmaker Gilead Sciences Inc of restricting access to its breakthrough hepatitis C drug Sovaldi in developing countries as it tries to protect profit margin in wealthier nations.

    3. How Cuba’s Health Care Sector Aims to Gain a Greater Foothold


      Wed, 18 Feb 2015

      countries and contributing to revenues of $1 billion a year in Cuban pharmaceutical exports. YM BioSciences was acquired by Giliad Sciences in 2013, and Singapore-based Innokeys acquired its stake in the joint venture with CIMAB. Iznaga-Escobar is now chief

    4. Gilead drags healthcare shares down on drug price worries


      Wed, 4 Feb 2015

      Feb 4 (Reuters) - Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C...

    5. Raising Our Gilead Fair Value Estimate on Higher HCV Treatment Numbers, Despite Higher Discounting


      Wed, 4 Feb 2015

      Gilead Sciences reported fourth-quarter results and ..... the next couple of years, we believe Gilead 's portfolio and pipeline are diverse ..... the firm's wide moat looks secure. Gilead 's $3.8 billion in hepatitis C revenue

    6. PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary


      Mon, 26 Jan 2015

      Jan 26 (Reuters) - Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc 's hepatitis C drugs on an exclusive basis, the latest...

    7. Morningstar's 2014 CEO of the Year


      Wed, 21 Jan 2015

      the Year. Under his leadership, Gilead Sciences ' focus on infectious disease has ..... oncology. Martin, who is also Gilead ’s chairman, has shown exemplary ..... independence and qualifications. Gilead 's moat was formed by its leadership

    8. CORRECTED-UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs


      Fri, 9 Jan 2015

      Jan 8 (Reuters) - Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc 's hepatitis C drug Harvoni will be the primary treatment for patients infected with the...

    9. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers


      Tue, 16 Dec 2014

      names during the year, including Applied Materials AMAT "> AMAT , Iron Mountain IRM "> IRM , Apple, and Gilead Sciences GILD "> GILD . Even so, its year-to-date performance is only marginally better than the performance of the S&P 500

    10. From Barron’s, December 15, 2014 (Part 2)


      Sat, 13 Dec 2014

      investorsentimentreadings.html Bullish stories: Carnival & Royal Caribbean Cruises [ CCL; RCL ; pg 21]; FMC [pg 23; see link below]; Gilead [ GILD ; pg 25]; Korean steel maker Posco [ PKX ; pg 25]; Nestle [NESN.sw/ NSRGY ; CEO spotlight on Paul Bulcke ; pg 56

    « Prev12345Next »
    Content Partners